Abstract：
The purpose of this American Urological Association (AUA) Guideline amendment is to provide a useful reference on the effective evidence-based management of male lower urinary tract symptoms secondary/attributed to BPH (LUTS/BPH).
The Minnesota Evidence Review Team searched Ovid MEDLINE, the Cochrane Library, and the Agency for Healthcare Research and Quality (AHRQ) database to identify studies relevant to the management of BPH. The guideline was updated in 2023 to capture eligible literature published between September 2020 and October 2022. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions.
The BPH amendment resulted in changes to statements/supporting text on combination therapy, photoselective vaporization of the prostate (PVP), water vapor thermal therapy (WVTT), laser enucleation, and prostate artery embolization (PAE). A new statement on temporary implanted prostatic devices (TIPD) was added. In addition, statements on transurethral needle ablation (TUNA) and transurethral microwave thermotherapy (TUMT) were removed and information regarding these legacy technologies was added to the background section. References and the accompanying treatment algorithms were updated to align with the updated text.
This guideline seeks to improve clinicians\' ability to evaluate and treat patients with BPH/LUTS based on currently available evidence. Future studies will be essential to further support these statements to improve patient care.
The Minnesota Evidence Review Team searched Ovid MEDLINE, the Cochrane Library, and the Agency for Healthcare Research and Quality (AHRQ) database to identify studies relevant to the management of BPH. The guideline was updated in 2023 to capture eligible literature published between September 2020 and October 2022. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions.
The BPH amendment resulted in changes to statements/supporting text on combination therapy, photoselective vaporization of the prostate (PVP), water vapor thermal therapy (WVTT), laser enucleation, and prostate artery embolization (PAE). A new statement on temporary implanted prostatic devices (TIPD) was added. In addition, statements on transurethral needle ablation (TUNA) and transurethral microwave thermotherapy (TUMT) were removed and information regarding these legacy technologies was added to the background section. References and the accompanying treatment algorithms were updated to align with the updated text.
This guideline seeks to improve clinicians\' ability to evaluate and treat patients with BPH/LUTS based on currently available evidence. Future studies will be essential to further support these statements to improve patient care.
摘要：
目的：美国泌尿外科协会（AUA）指南修订的目的是为男性下尿路继发/归因于BPH（LUTS/BPH）的有效循证管理提供有用的参考。
方法：明尼苏达州证据审查小组搜索了OvidMEDLINE，Cochrane图书馆,以及医疗保健研究与质量局（AHRQ）数据库，以确定与BPH管理相关的研究。该指南于2023年进行了更新，以捕获2020年9月至2022年10月之间发表的合格文献。如果有足够的证据，证据体被指定为强度等级A（高），B(中等),或C（低）支持强，中等,或有条件的建议。在缺乏充分证据的情况下,其他信息作为临床原则和专家意见提供。
结果：BPH修正案导致了关于联合治疗的陈述/支持文本的变化，前列腺光选择性汽化术（PVP），水蒸气热疗（WVTT），激光摘除,和前列腺动脉栓塞术（PAE）。增加了关于临时植入前列腺装置（TIPD）的新声明。此外,删除了关于经尿道针式消融术(TUNA)和经尿道微波热疗(TUMT)的陈述,并将有关这些传统技术的信息添加到了背景技术部分.更新参考文献和伴随的治疗算法以与更新的文本对齐。
结论：本指南旨在根据现有证据提高临床医生评估和治疗BPH/LUTS患者的能力。未来的研究对于进一步支持这些陈述以改善患者护理至关重要。
方法：明尼苏达州证据审查小组搜索了OvidMEDLINE，Cochrane图书馆,以及医疗保健研究与质量局（AHRQ）数据库，以确定与BPH管理相关的研究。该指南于2023年进行了更新，以捕获2020年9月至2022年10月之间发表的合格文献。如果有足够的证据，证据体被指定为强度等级A（高），B(中等),或C（低）支持强，中等,或有条件的建议。在缺乏充分证据的情况下,其他信息作为临床原则和专家意见提供。
结果：BPH修正案导致了关于联合治疗的陈述/支持文本的变化，前列腺光选择性汽化术（PVP），水蒸气热疗（WVTT），激光摘除,和前列腺动脉栓塞术（PAE）。增加了关于临时植入前列腺装置（TIPD）的新声明。此外,删除了关于经尿道针式消融术(TUNA)和经尿道微波热疗(TUMT)的陈述,并将有关这些传统技术的信息添加到了背景技术部分.更新参考文献和伴随的治疗算法以与更新的文本对齐。
结论：本指南旨在根据现有证据提高临床医生评估和治疗BPH/LUTS患者的能力。未来的研究对于进一步支持这些陈述以改善患者护理至关重要。
